US President Donald Trump at last revealed his ‘Blueprint for drug pricing’ which was not as bad as some in the investment community and pharma industry had expected. On the M&A and deal-making front, Eli Lilly announced a second acquisition within a matter of days, that of AurKa Pharma, while bluebird bio entered into a new agreement with Medigene for two additional TCR targets to take a lead in immuno-oncology. Research and regulatory news attracting attention last week included positive trial results for Eli Lilly’s neurological candidate galcanezumab in epsodic cluster headache, which is currently under Food and Drug Administration review for migraine, and the landmark US approval of Aimovig from Amgen and Novartis for migraine, a rival to Lilly’s candidate.
Trump drug pricing blueprint limited by current HHS authority
Following the announcement, Leering Research analyst Geoffrey Porges hosted a MEDACorp PULSE call with a Washington healthcare policy specialist on the initial reactions to US President Trump and Health and Human Services (HHS) Secretary Alex Azar’s American Patients First Blueprint.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze